AR041566A1 - Derivados de indol utiles para el tratamiento de enfermedades - Google Patents
Derivados de indol utiles para el tratamiento de enfermedadesInfo
- Publication number
- AR041566A1 AR041566A1 ARP030103677A ARP030103677A AR041566A1 AR 041566 A1 AR041566 A1 AR 041566A1 AR P030103677 A ARP030103677 A AR P030103677A AR P030103677 A ARP030103677 A AR P030103677A AR 041566 A1 AR041566 A1 AR 041566A1
- Authority
- AR
- Argentina
- Prior art keywords
- diseases
- hydrogen
- alkyl
- treatment
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Se refiere a derivados de indol y a procedimientos para la preparación de intermediarios usados en la preparación de composiciones que los contienen y el uso de dichos derivados. Los derivados de indol según la presente invención son útiles en numerosas enfermedades, trastornos y afecciones, en particular enfermedades,trastornos y afecciones inflamatorias, alérgicas y respiratorias. Reivindicación 1: Un compuesto de fórmula 1 caracterizado porque n es un número entero igual a 0, 1, 2, 3 o 4; R1 y R2 son cada uno de ellos independientemente seleccionados de hidrógeno y alquilo (C1-4); R3 se selecciona del grupo constituído por hidrógeno o alquilo ( C1-6) sustituido opcionalemtne con un hidroxi; y R4, R5, R6, R7 y R8 cada uno de ellos se selecci0ona independientemente del grupo constituido por hidrógeno, hidroxi, alquilo (C1-6), alcoxi (C1-6), benciloxi, hidroxialquilo (C1-6), tioalquilo (C1-6), halo y trifluorometilo, o una sal y/o isómero, tautómero, solvato o variación isotópica faramcéuticamente aceptables del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20020292513 EP1407769A1 (en) | 2002-10-11 | 2002-10-11 | Indole derivatives as beta-2 agonists |
EP03290069A EP1440966A1 (en) | 2003-01-10 | 2003-01-10 | Indole derivatives useful for the treatment of diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
AR041566A1 true AR041566A1 (es) | 2005-05-18 |
Family
ID=32095049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030103677A AR041566A1 (es) | 2002-10-11 | 2003-10-09 | Derivados de indol utiles para el tratamiento de enfermedades |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1556034B1 (es) |
JP (1) | JP4490911B2 (es) |
KR (1) | KR20050047552A (es) |
AP (1) | AP2005003283A0 (es) |
AR (1) | AR041566A1 (es) |
AT (1) | ATE392206T1 (es) |
AU (1) | AU2003269316A1 (es) |
BR (1) | BR0315234A (es) |
CA (1) | CA2499314C (es) |
CO (1) | CO5550421A2 (es) |
DE (1) | DE60320439T2 (es) |
EA (1) | EA200500618A1 (es) |
EC (1) | ECSP055780A (es) |
ES (1) | ES2302938T3 (es) |
IS (1) | IS7751A (es) |
MA (1) | MA27452A1 (es) |
MX (1) | MXPA05003866A (es) |
NO (1) | NO20051406L (es) |
OA (1) | OA12938A (es) |
PA (1) | PA8586001A1 (es) |
PE (1) | PE20040775A1 (es) |
PL (1) | PL376396A1 (es) |
TW (1) | TW200424171A (es) |
UY (1) | UY28013A1 (es) |
WO (1) | WO2004032921A1 (es) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR028948A1 (es) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
EP1460064A1 (en) | 2003-03-14 | 2004-09-22 | Pfizer Limited | Indole-2-carboxamide derivatives useful as beta-2 agonists |
GB0312832D0 (en) * | 2003-06-04 | 2003-07-09 | Pfizer Ltd | 2-amino-pyridine derivatives useful for the treatment of diseases |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
WO2005092841A1 (en) * | 2004-03-23 | 2005-10-06 | Pfizer Limited | Compounds having beta-agonist activity |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
AR049384A1 (es) | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
CA2618089A1 (en) | 2005-08-08 | 2007-02-15 | Argenta Discovery Ltd. | Bicyclo[2.2.]hept-7-ylamine derivatives and their uses |
EP2532679B1 (en) | 2005-10-21 | 2017-04-12 | Novartis AG | Human antibodies against il13 and therapeutic uses |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
MEP9608A (en) | 2006-03-20 | 2010-06-10 | Pfizer Ltd | Amine derivatives |
PT2013211E (pt) | 2006-04-21 | 2012-06-21 | Novartis Ag | Derivados de purina para utilização como agonistas de receptores a2a de adenosina |
TW200821316A (en) | 2006-07-19 | 2008-05-16 | Astrazeneca Ab | Novel compounds 243 |
TW200825084A (en) | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
US20100113510A1 (en) | 2006-12-19 | 2010-05-06 | Rhonan Ford | Quinuclidinol derivatives as muscarinic receptor antagonists |
CA2673803A1 (en) | 2007-01-10 | 2008-07-17 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
EP2117541A1 (en) | 2007-02-09 | 2009-11-18 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
ATE499363T1 (de) | 2007-05-07 | 2011-03-15 | Novartis Ag | Organische verbindungen |
WO2009074575A2 (en) | 2007-12-10 | 2009-06-18 | Novartis Ag | Organic compounds |
ES2442930T3 (es) | 2008-01-11 | 2014-02-14 | Novartis Ag | Pirimidinas como inhibidores de cinasas |
EP2300464A1 (en) | 2008-05-13 | 2011-03-30 | AstraZeneca AB | Quinuclidine derivatives as muscarinic m3 receptor antagonists |
US8273774B2 (en) | 2008-05-27 | 2012-09-25 | Astrazeneca Ab | Phenoxypyridinylamide compounds |
BRPI0915018A2 (pt) | 2008-06-10 | 2015-10-27 | Novartis Ag | compostos orgânicos |
US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
WO2010067102A1 (en) | 2008-12-09 | 2010-06-17 | Astrazeneca Ab | Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders |
EP2379507B1 (en) | 2008-12-30 | 2013-10-16 | Pulmagen Therapeutics (Inflammation) Limited | Sulfonamide compounds for the treatment of respiratory disorders |
WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
JP5801997B2 (ja) | 2009-07-07 | 2015-10-28 | ファイザー・リミテッドPfizer Limited | 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器 |
WO2011050325A1 (en) | 2009-10-22 | 2011-04-28 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
GB201016912D0 (en) | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
US9102671B2 (en) | 2011-02-25 | 2015-08-11 | Novartis Ag | Compounds and compositions as TRK inhibitors |
AR085509A1 (es) | 2011-03-09 | 2013-10-09 | Bayer Cropscience Ag | Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas |
CA2838765C (en) | 2011-06-10 | 2019-05-07 | Chiesi Farmaceutici S.P.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
ES2558457T3 (es) | 2011-09-16 | 2016-02-04 | Novartis Ag | Compuestos heterocíclicos para el tratamiento de fibrosis quística |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038390A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | N-substituted heterocyclyl carboxamides |
US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
EP2928889B1 (en) | 2012-12-06 | 2018-03-21 | Chiesi Farmaceutici S.p.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
TW201427977A (zh) | 2012-12-06 | 2014-07-16 | Chiesi Farma Spa | 具有蕈毒鹼受體拮抗劑及β2腎上腺素受體致效劑活性之化合物 |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
AR099336A1 (es) | 2014-02-17 | 2016-07-13 | Bayer Cropscience Ag | Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas |
US10004732B2 (en) | 2014-04-24 | 2018-06-26 | Novartis Ag | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
US9862711B2 (en) | 2014-04-24 | 2018-01-09 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
CA2945069A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors |
JP2022537667A (ja) | 2019-06-10 | 2022-08-29 | ノバルティス アーゲー | Cf、copd、及び気管支拡張症の治療のためのピリジン及びピラジン誘導体 |
AU2020338971B2 (en) | 2019-08-28 | 2023-11-23 | Novartis Ag | Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease |
WO2021260441A1 (en) | 2020-06-26 | 2021-12-30 | Mylan Pharma Uk Limited | Formulations including 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0703911B1 (en) * | 1993-06-14 | 1997-07-02 | Pfizer Inc. | Secondary amines as antidiabetic and antiobesity agents |
EP0801060A1 (en) * | 1996-04-09 | 1997-10-15 | Pfizer Inc. | Heterocyclic Beta-3 Adrenergenic Agonists |
US5859044A (en) * | 1996-07-31 | 1999-01-12 | Pfizer Inc. | β-adrenergic agonists |
-
2003
- 2003-10-06 EA EA200500618A patent/EA200500618A1/ru unknown
- 2003-10-06 BR BR0315234-0A patent/BR0315234A/pt not_active IP Right Cessation
- 2003-10-06 JP JP2005501006A patent/JP4490911B2/ja not_active Expired - Fee Related
- 2003-10-06 KR KR1020057006090A patent/KR20050047552A/ko not_active Application Discontinuation
- 2003-10-06 PL PL03376396A patent/PL376396A1/xx unknown
- 2003-10-06 AU AU2003269316A patent/AU2003269316A1/en not_active Abandoned
- 2003-10-06 CA CA2499314A patent/CA2499314C/en not_active Expired - Fee Related
- 2003-10-06 AP AP2005003283A patent/AP2005003283A0/xx unknown
- 2003-10-06 OA OA1200500099A patent/OA12938A/en unknown
- 2003-10-06 DE DE60320439T patent/DE60320439T2/de not_active Expired - Lifetime
- 2003-10-06 ES ES03751095T patent/ES2302938T3/es not_active Expired - Lifetime
- 2003-10-06 EP EP03751095A patent/EP1556034B1/en not_active Expired - Lifetime
- 2003-10-06 AT AT03751095T patent/ATE392206T1/de not_active IP Right Cessation
- 2003-10-06 MX MXPA05003866A patent/MXPA05003866A/es not_active Application Discontinuation
- 2003-10-06 WO PCT/IB2003/004441 patent/WO2004032921A1/en active IP Right Grant
- 2003-10-09 AR ARP030103677A patent/AR041566A1/es unknown
- 2003-10-09 PE PE2003001024A patent/PE20040775A1/es not_active Application Discontinuation
- 2003-10-09 TW TW092128121A patent/TW200424171A/zh unknown
- 2003-10-10 PA PA20038586001A patent/PA8586001A1/es unknown
- 2003-10-10 UY UY28013A patent/UY28013A1/es not_active Application Discontinuation
-
2005
- 2005-03-17 NO NO20051406A patent/NO20051406L/no unknown
- 2005-03-17 IS IS7751A patent/IS7751A/is unknown
- 2005-04-08 CO CO05032119A patent/CO5550421A2/es not_active Application Discontinuation
- 2005-04-11 MA MA28210A patent/MA27452A1/fr unknown
- 2005-05-05 EC EC2005005780A patent/ECSP055780A/es unknown
Also Published As
Publication number | Publication date |
---|---|
DE60320439T2 (de) | 2009-05-20 |
MA27452A1 (fr) | 2005-07-01 |
UY28013A1 (es) | 2004-04-30 |
ECSP055780A (es) | 2005-08-11 |
EP1556034B1 (en) | 2008-04-16 |
PL376396A1 (en) | 2005-12-27 |
KR20050047552A (ko) | 2005-05-20 |
EA200500618A1 (ru) | 2005-12-29 |
ATE392206T1 (de) | 2008-05-15 |
ES2302938T3 (es) | 2008-08-01 |
DE60320439D1 (de) | 2008-05-29 |
WO2004032921A1 (en) | 2004-04-22 |
TW200424171A (en) | 2004-11-16 |
CA2499314A1 (en) | 2004-04-22 |
CA2499314C (en) | 2010-08-24 |
MXPA05003866A (es) | 2005-06-22 |
JP4490911B2 (ja) | 2010-06-30 |
BR0315234A (pt) | 2005-08-23 |
OA12938A (en) | 2006-10-13 |
AP2005003283A0 (en) | 2005-06-30 |
CO5550421A2 (es) | 2005-08-31 |
PA8586001A1 (es) | 2005-02-04 |
IS7751A (is) | 2005-03-17 |
JP2006511596A (ja) | 2006-04-06 |
PE20040775A1 (es) | 2004-12-10 |
AU2003269316A1 (en) | 2004-05-04 |
NO20051406L (no) | 2005-04-22 |
EP1556034A1 (en) | 2005-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
CO5700824A2 (es) | Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen | |
UY28578A1 (es) | Derivados de amida | |
AR037329A1 (es) | Compuestos pirazolo pirimidinona, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y usos de los mismos en la preparacion de medicamentos | |
AR035617A1 (es) | Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios | |
SE0104332D0 (sv) | Therapeutic agents | |
AR032130A1 (es) | Un compuesto inhibidor de quinasas proteicas, una composicion farmaceutica que lo incluye, y un metodo para tratar afecciones con dicho compuesto | |
EA200500174A1 (ru) | Новые производные бензимидазола, полезные в качестве антипролиферативных агентов | |
AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
UY28339A1 (es) | Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades | |
AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
MX2007004183A (es) | Derivados de benzoimidazol utiles como agentes antiproliferacion. | |
AR034268A1 (es) | Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion | |
PE20050013A1 (es) | Composiciones farmaceuticas como inhibidores de la proteasa del virus de la hepatitis c | |
AR036233A1 (es) | Un compuesto derivado de indol, su uso, procesos para prepararlo y una composicion farmaceutica que lo comprende | |
ECSP045073A (es) | Nuevos derivados de piperazina | |
ECSP045004A (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes | |
ECSP034744A (es) | Antagonistas de nmda/nr2b no arilo-heterociclico n-sustituidos | |
AR066881A1 (es) | Derivados de oxadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de trastornos asociados con la disfuncion del glutamato. | |
EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
UY28135A1 (es) | Derivados de pirimidina para el tratamiento de crecimiento celular anormal | |
RU2007138937A (ru) | Производные 1-бензилиндол-2-карбоксамида | |
AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
YU45095A (sh) | Derivati benzimidazola, postupci za njihovo prirpremanje i primena tih derivata u medicinskoj terapiji, naročito za lečenje ili sprečavanje virusnih infekcija | |
AR065772A1 (es) | Compuestos de indolobenzazepina para el tratamiento de la hepatitis c. composiciones farmaceuticas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |